COLL vs EFX · P/E 17, rev $181.9M vs P/E 54, rev $5.68B
Collegium Pharmaceutical Inc (COLL) versus Equifax Inc (EFX) — a side-by-side from cached financials, not a winner call.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Equifax Inc (EFX) is a consulting services company listed on US.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Latest reported EFX revenue for 2024-12-31 was $5.68B. Net income was $607.3M. Revenue was up 7.9% from 2023-12-31 to 2024-12-31. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
Not investment advice. Open the COLL and EFX stock pages for the full models.
Not investment advice.